3.33% +0.013

AIM ImmunoTech Inc (AIM)

AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten

AIM ImmunoTech Inc (AIM)

AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten

AIM ImmunoTech Inc. (AMEX:AIM) Q1 2024 Earnings Call Transcript - Insider Monkey

Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials - Investing.com South Africa

Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials - Investing.com India

Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials - Investing.com

AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024 - InvestorPlace

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

Investing in AIM ImmunoTech Inc (AIM): What You Must Know – Knox Daily - Knox Daily

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and… - Informazione.it

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and ... - GlobeNewswire

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and ... - Yahoo Finance

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and ... - GlobeNewswire

Aim ImmunoTech COO acquires $12,500 in company stock By Investing.com - Investing.com Australia

Aim ImmunoTech CEO buys $25,000 in company stock By Investing.com - Investing.com Canada

Aim ImmunoTech CEO buys $25000 in company stock - Investing.com India

Aim ImmunoTech COO acquires $12,500 in company stock By Investing.com - Investing.com

Aim ImmunoTech CEO buys $25,000 in company stock By Investing.com - Investing.com

Aim ImmunoTech CEO buys $25,000 in company stock By Investing.com - Investing.com UK

Aim ImmunoTech COO acquires $12,500 in company stock By Investing.com - Investing.com

AIM Completes Ampligen Turnout | MENAFN.COM - MENAFN.COM

AIM Completes Ampligen Turnout - Baystreet.ca

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® - Yahoo Finance

AIM ImmunoTech reports progress in pancreatic cancer drug trial - Clinical Trials Arena

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi ... - Yahoo Finance

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewswire

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ... - GlobeNewswire

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech 宣布 Ampligen 与 Pembrolizumab 联合用药治疗复发性卵巢癌的研究取得积极顶线、方案计划中期报告数据

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen ... - Yahoo Finance

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript - Yahoo Finance

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023 - InvestorPlace

Navigating the Future: Aim Immunotech's Challenge Against Rapid Tech Evolution in Pharma - TipRanks.com - TipRanks

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference - GlobeNewswire

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host ... - Yahoo Finance

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of ... - Yahoo Finance

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Yahoo Finance

Aim ImmunoTech CEO buys $25,000 in company stock By Investing.com - Investing.com

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

Ähnlich wie AIM